BioTechGrid

A phase 3b trial of Otsuka’s attention-deficit/hyperactivity disorder (ADHD) prospect has hit its primary endpoint, strengthening the drugmaker’s hand weeks before…

Ionis Pharmaceuticals has offloaded regional rights to its near-approval rare disease asset zilganersen, pocketing $30 million upfront from Recordati for an…

In recent years, the pervasive contamination of ecosystems by microplastics (MPs) and nanoplastics (NPs) has emerged as a critical environmental…

In a landmark study poised to redefine the landscape of protein synthesis, Professor Joongoo Lee and his team at POSTECH…

In the quest for sustainable and efficient energy storage solutions, hydrogen stands out as a beacon of promise. Its potential…

Natural hallucinogens—psychoactive compounds such as psilocybin, mescaline, and N,N-dimethyltryptamine (DMT)—have long captured human fascination due to their profound effects on…

In a remarkable advancement at the intersection of computational biology and drug design, researchers have unveiled a novel approach that…

In a groundbreaking study published in Nature Communications, researchers have unveiled a comprehensive comparative genomic analysis of fungi intimately associated…